Published Online
on September 13, 2004

A more recent version of this article appeared on September 21, 2004

This Article Full Text (PDF) All Versions of this Article: 110/12/1572    most recent 01.CIR.0000142047.28024.F2v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions patientINFORMation Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aguilar, D. Articles by Pfeffer, M. A. Search for Related Content PubMed PubMed Citation Articles by Aguilar, D. Articles by Pfeffer, M. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAPTOPRIL Medline Plus Health Information Diabetes Diabetes Complications Heart Attack Related Collections Type 2 diabetes Acute myocardial infarction

Submitted on January 29, 2004
Revised on April 29, 2004
Accepted on May 18, 2004

Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. The Valsartan in Acute Myocardial Infarction (VALIANT) Trial

David Aguilar MD^*, Scott D. Solomon MD, Lars Køber MD, DSc, Jean-Lucien Rouleau MD, Hicham Skali MD, John J.V. McMurray MD, Gary S. Francis MD, Marc Henis MD, Christopher M. O’Connor MD, Rafael Diaz MD, Yuri N. Belenkov MD, PhD, Sergei Varshavsky MD, Jeffrey D. Leimberger PhD, Eric J. Velazquez MD, Robert M. Califf MD, and Marc A. Pfeffer MD, PhD

From the University of Texas Health Science Center, Houston (D.A.); Brigham and Women’s Hospital, Boston, Mass (S.D.S., H.S., M.A.P.); Rigshospitalet, Copenhagen, Denmark (L.K.); Toronto Hospital, Toronto, Ontario, Canada (J.L.R.); University of Glasgow, Glasgow, United Kingdom (J.J.V.M.); The Cleveland Clinic Foundation, Cleveland, Ohio (G.S.F.); Medical Pharmaceutical Consultants, Randolph, NJ (M.H.); Duke Clinical Research Institute, Durham, NC (C.M.O., J.D.L., E.J.V, R.M.C.); Estudios Cardiologicos Latinoamerica, Santa Fe, Argentina (R.D.); Cardiology Research Institute, Moscow, Russia (Y.N.B.); and the CPR/Research Institute of Cardiology, St. Petersburg, Russia (S.V.).

^* To whom correspondence should be addressed. E-mail: david.aguilar{at}uth.tmc.edu.

Background--A prior diagnosis of diabetes mellitus is associated with adverse outcomes after acute myocardial infarction (MI), but the risk associated with a new diagnosis of diabetes in this setting has not been well defined.

Methods and Results--We assessed the risk of death and major cardiovascular events associated with previously known and newly diagnosed diabetes by studying 14 703 patients with acute MI enrolled in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Patients were grouped by diabetic status: previously known diabetes (insulin use or diagnosis of diabetes before MI, n=3400, 23%); newly diagnosed diabetes (use of diabetic therapy or diabetes diagnosed at randomization [median 4.9 d after infarction], but no known diabetes at presentation, n=580, 4%); or no diabetes (n=10 719). Patients with newly diagnosed diabetes were younger and had fewer comorbid conditions than did patients with previously known diabetes. At 1 year after enrollment, patients with previously known and newly diagnosed diabetes had similarly increased adjusted risks of mortality (hazard ratio [HR] 1.43; 95% confidence interval [CI], 1.29 to 1.59 and HR, 1.50; 95% CI, 1.21 to 1.85, respectively) and cardiovascular events (HR, 1.37; 95% CI, 1.27 to 1.48 and HR, 1.34; 95% CI, 1.14 to 1.56).

Conclusions--Diabetes mellitus, whether newly diagnosed or previously known, is associated with poorer long-term outcomes after MI in high-risk patients. The poor prognosis of patients with newly diagnosed diabetes, despite having baseline characteristics similar to those of patients without diabetes, supports the idea that metabolic abnormalities contribute to their adverse outcomes.

Key words: myocardial infarction • prognosis • diabetes mellitus • heart failure

Find additional patient-related information at:

Who is at Greater Risk for Heart Problems: Newly or Previously Diagnosed Patients With Diabetes?

This article has been cited by other articles:

				G.-Y. Song, Y.-J. Wu, Y.-J. Yang, J.-J. Li, H.-L. Zhang, H.-J. Pei, Z.-Y. Zhao, Z.-H. Zeng, and R.-T. Hui The accelerated post-infarction progression of cardiac remodelling is associated with genetic changes in an untreated streptozotocin-induced diabetic rat model Eur J Heart Fail, October 1, 2009; 11(10): 911 - 921. [Abstract] [Full Text] [PDF]

				S. Matsushima, S. Kinugawa, T. Yokota, N. Inoue, Y. Ohta, S. Hamaguchi, and H. Tsutsui Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H409 - H416. [Abstract] [Full Text] [PDF]

				A. Meris, M. Amigoni, H. Uno, J. J. Thune, A. Verma, L. Kober, M. Bourgoun, J. J. McMurray, E. J. Velazquez, A. P. Maggioni, et al. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study Eur. Heart J., January 1, 2009; 30(1): 56 - 65. [Abstract] [Full Text] [PDF]

				A. Dzudie, A. P. Kengne, S. Mbahe, A. Menanga, M. Kenfack, and S. Kingue Chronic heart failure, selected risk factors and co-morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon Eur J Heart Fail, April 1, 2008; 10(4): 367 - 372. [Abstract] [Full Text] [PDF]

				R Peter, A Cox, and M Evans Management of diabetes in cardiovascular patients Heart, March 1, 2008; 94(3): 369 - 375. [Full Text] [PDF]

				P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF]

				M. Ishihara, I. Inoue, T. Kawagoe, Y. Shimatani, S. Kurisu, T. Hata, Y. Nakama, Y. Kijima, and E. Kagawa Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur. Heart J., October 2, 2006; 27(20): 2413 - 2419. [Abstract] [Full Text] [PDF]

				S. Sulfi and A. D Timmis Review: Heart failure complicating acute myocardial infarction in patients with diabetes: pathophysiology and management strategies The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 191 - 196. [Abstract] [PDF]

				S. P. Marso, D. M. Safley, J. A. House, T. Tessendorf, K. J. Reid, and J. A. Spertus Suspected Acute Coronary Syndrome Patients With Diabetes and Normal Troponin-I Levels Are at Risk for Early and Late Death: Identification of a new high-risk acute coronary syndrome population Diabetes Care, August 1, 2006; 29(8): 1931 - 1932. [Full Text] [PDF]

				Z. T. Bloomgarden Cardiovascular Disease Diabetes Care, May 1, 2006; 29(5): 1160 - 1166. [Full Text] [PDF]

				M. Bartnik, K. Malmberg, and L. Ryden Management of patients with type 2 diabetes after acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 144 - 154. [Abstract] [PDF]

				D. S. Pinto, A. H. Skolnick, A. J. Kirtane, S. A. Murphy, H. V. Barron, R. P. Giugliano, C. P. Cannon, E. Braunwald, C. M. Gibson, and for the TIMI Study Group U-Shaped Relationship of Blood Glucose With Adverse Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction J. Am. Coll. Cardiol., July 5, 2005; 46(1): 178 - 180. [Full Text] [PDF]

				Metabolic Link Between Diabetes and MI DOC News, January 1, 2005; 2(1): 22 - 22. [Full Text]

				Minerva BMJ, December 11, 2004; 329(7479): E335 - E335. [Full Text] [PDF]

				New Diabetes Linked with Poor Outcomes After MI Journal Watch (General), October 22, 2004; 2004(1022): 1 - 1. [Full Text]

				Minerva BMJ, October 2, 2004; 329(7469): 808 - 808. [Full Text] [PDF]